Pipeline

Product Development Pipeline

TScan’s technology platform has the potential to uncover new targets in a variety of diseases, including cancer, autoimmunity, and infectious disease. TScan is initially focused on cancer, with programs in both liquid and solid tumors.

NAME
DISCOVERY
LEAD OPTIMIZATION
IND-ENABLING
CLINICAL

Liquid Tumor Program

TSC-100
HA-1 TCR-T
IND-enabling

TSC-101
HA-2 TCR-T
IND-enabling

Solid Tumor Program

TSC-200
HPV16 TCR-T
Lead Optimization

TSC-201
Target 201 TCR-T
Lead Optimization

TSC-202
Target 202 TCR-T
Lead Optimization

TSC-203
PRAME TCR-T
Lead Optimization

Liquid Tumor Program

  • TScan’s lead clinical program is designed to treat leukemia following hematopoietic stem cell transplant (HSCT) therapy.
  • HSCT remains the standard-of-care therapy for a variety of hematologic malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
  • Despite advances in HSCT, 30-40% of patients relapse following therapy, and relapsing patients face poor prognosis.
  • However, rare patients naturally develop T cells targeting minor histocompatibility antigens such as HA-1 and HA-2, and these patients exhibit lower relapse rates.

Many Patients Relapse Following HSCT Therapy

  • Engineered T cells targeting minor histocompatibility antigens such as HA-1 eliminate residual disease without affecting new donor-derived blood cells.
  • Using our internal discovery capabilities, TScan is developing a set of TCR-T therapies targeting minor histocompatibility antigens that will offer a comprehensive solution for patients following HSCT.

TScan Strategy to Decrease Relapse Rates Following HSCT Therapy

  • TSC-100 and TSC-101 are the lead minor histocompatibility antigen-specific TCRs in this program, targeting HA-1 and HA-2 respectively, with INDs planned for 2021.
  • TScan is leveraging its novel target ID capabilities to identify and develop additional minor histocompatibility antigen TCRs to expand this program to all patients in need.

TScan is Developing a Comprehensive Solution to Treat Every Patient

Solid Tumor Program

  • TScan is concurrently developing a multiplexed TCR-T therapy program to treat solid tumors.
  • Leveraging our disruptive technology platform that enables us to rapidly discover new targets and TCRs directly from the tumor-infiltrating T cells of patients that are actively responding to immunotherapy, we are building a growing collection of therapeutically active and safe TCRs with diverse anti-tumor targets.
  • Ultimately, this repository will be used to provide customized therapies for diverse groups of patients based on their specific tumor and HLA type.
  • TCR-T therapies will be also be multiplexed to overcome solid tumor heterogeneity and potential resistance due to target loss.
  • All therapeutic TCRs are de-risked using TScan’s comprehensive safety screen for off-target effects.

TScan Strategy for Multiplexed TCR-T Therapy for Solid Tumors